tiprankstipranks
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksStock ScreenerCompare StocksPenny Stock ScreenerTop Product Insights Stocks
Daily Updates
Daily Analyst RatingsTrending StocksTop Stock GainersTop Stock LosersMost Active StocksDividend StocksChatGPT Stocks
New
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarMarket Holidays
ETF Research Tools
ETF CenterETF ScreenerTop ETFs by Smart Score
New
Compare ETFsTop ETFs by AUM
ETFs On the Move
Top ETF GainersTop ETF LosersMost Active ETFs
ETF Ideas
S&P 500 Index ETFsNasdaq 100 Index ETFsS&P 500 Sector ETFsBond ETFsCommodity ETFsCurrency ETFsIndustry ETFs
Best Dividend StocksBest High Yield Dividend StocksDividend Aristocrats
New
Dividend Stock ComparisonDividend Calculator
Popular
Dividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
My PortfolioMy WatchlistMy PerformanceMy Portfolio AnalysisCrowd Insights
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
Education
TipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityCareersContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Stock Screener
Compare Stocks
Penny Stock Screener
Top Product Insights Stocks
Options Profit Calculator
New
Daily Updates
Daily Analyst Ratings
Trending Stocks
Top Stock Gainers
Top Stock Losers
Most Active Stocks
Dividend Stocks
ChatGPT Stocks
New
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Market Holidays
ETF Research Tools
ETF Center
ETF Screener
New
Top ETFs by Smart Score
New
Compare ETFs
Top ETFs by AUM
ETFs On the Move
Top ETF Gainers
Top ETF Losers
Most Active ETFs
ETF Ideas
S&P 500 Index ETFs
Nasdaq 100 Index ETFs
S&P 500 Sector ETFs
Bond ETFs
Commodity ETFs
Currency ETFs
Industry ETFs
Best Dividend Stocks
Best High Yield Dividend Stocks
Dividend Aristocrats
New
Dividend Stock Comparison
Dividend Calculator
Popular
Dividend Returns Comparison
Dividend Calendar
Crypto Center
Bitcoin
Ethereum
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
My Portfolio
My Watchlist
My Performance
My Portfolio Analysis
Crowd Insights
Stock Market News
Stock Analysis & Ideas
Popular
ETF News
Global Markets News
Expert Spotlight
TipRanks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
Education
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Careers
Contact Us
Working with TipRanks
Enterprise Solutions
Best Online Brokers
Become an Affiliate
Follow Us
Plans & Pricing

AEZS Stock Latest News

Aeterna Zentaris Reports First Quarter 2023 Financial Results
Press ReleasesAeterna Zentaris Reports First Quarter 2023 Financial Results
1M ago
AEZS
AEZS Upcoming Earnings Report: What to Expect?
Pre-EarningsAEZS Upcoming Earnings Report: What to Expect?
1M ago
AEZS
Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial
Press ReleasesAeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial
2M ago
AEZS
Aeterna Zentaris issued notice of allowance for USPTO for macimorelin patent
The FlyAeterna Zentaris issued notice of allowance for USPTO for macimorelin patent
2M ago
AEZS
Aeterna Zentaris says sales of Macrilen to be temporarily discontinued in U.S.
The FlyAeterna Zentaris says sales of Macrilen to be temporarily discontinued in U.S.
2M ago
NVO
AEZS
Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results
Press ReleasesAeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results
3M ago
AEZS
Aeterna Zentaris reports Q4 revenue $2.5M vs. $1M last year
The FlyAeterna Zentaris reports Q4 revenue $2.5M vs. $1M last year
3M ago
AEZS
Aeterna Zentaris announces Pharmanovia has acquired rights to GHRYVELIN
The FlyAeterna Zentaris announces Pharmanovia has acquired rights to GHRYVELIN
3M ago
AEZS
Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)
Press ReleasesPharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)
3M ago
AEZS
Aeterna Zentaris expects cash to fund operations into 2025
The FlyAeterna Zentaris expects cash to fund operations into 2025
5M ago
AEZS
Aeterna Zentaris provides therapeutics development pipeline update
The FlyAeterna Zentaris provides therapeutics development pipeline update
5M ago
AEZS
Aeterna Zentaris discontinues vaccine development pipeline
The FlyAeterna Zentaris discontinues vaccine development pipeline
5M ago
AEZS
Aeterna Zentaris provides business update, upcoming milestones
The FlyAeterna Zentaris provides business update, upcoming milestones
5M ago
AEZS
Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones
Press ReleasesAeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones
5M ago
AEZS
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event
Press ReleasesAeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event
5M ago
AEZS
Aeterna Zentaris Reports Third Quarter 2022 Financial Results
Press ReleasesAeterna Zentaris Reports Third Quarter 2022 Financial Results
7M ago
AEZS
Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk
Press ReleasesAeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk
9M ago
AEZS
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights
Press ReleasesAeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights
10M ago
AEZS
Aeterna Zentaris Announces Effective Date of Share Consolidation
Press ReleasesAeterna Zentaris Announces Effective Date of Share Consolidation
11M ago
AEZS
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
Press ReleasesAeterna Zentaris Announces Shareholder Approval of Share Consolidation
11M ago
AEZS